Recently Vaz-Luis et al in a series with more than 4000 patients with T1abN0 tumours, 520 of which with HER-2+ disease, reported distant relapse at 5 years for patients not treated with chemotherapy or trastuzumab that did not exceed 7% [10]. This evidence concerns the gene ERBB2 and neoplasm.